Pancreatic Cancer Research

ResearcherTexas Tech UniversityActive in the last 2 years

Vadivel Ganapathy

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-0799-6018; OpenAlex author ID A5091451352. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 3 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 9

  1. Dual targeting of SLC6A14 and autophagy/macropinocytosis enhances therapeutic efficacy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1042/bcj20250155↗
  2. Amino acid transporter SLC38A5 is a tumor promoter and a novel therapeutic target for pancreatic cancer. Co-author DOI 10.1038/s41598-023-43983-1↗
  3. Deletion of Slc6a14 reduces cancer growth and metastatic spread and improves survival in KPC mouse model of spontaneous pancreatic cancer. Co-author DOI 10.1042/bcj20210855↗
  4. PEPT1 is essential for the growth of pancreatic cancer cells: a viable drug target. Co-author DOI 10.1042/bcj20210377↗
  5. Chronic exposure to excess iron promotes EMT and cancer via p53 loss in pancreatic cancer. Last author DOI 10.1016/j.ajps.2020.02.003↗
  6. Synergism between SLC6A14 blockade and gemcitabine in pancreactic cancer: a 1H-NMR-based metabolomic study in pancreatic cancer cells. Co-author DOI 10.1042/bcj20200275↗
  7. Endocytosis of ATB0,+(SLC6A14)-targeted liposomes for drug delivery and its therapeutic application for pancreatic cancer. Co-author DOI 10.1080/17425247.2020.1723544↗
  8. Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer. Co-author DOI 10.1111/bph.13616↗
  9. SLC5A8 nuclear translocation and loss of expression are associated with poor outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0b013e31823f429f↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yangzom Doma Bhutia · 7 shared papers, 2016–2026 · strength 1.02
  2. Ruijie Chen · 3 shared papers, 2020–2026 · strength 0.51
  3. Longfa Kou · 3 shared papers, 2020–2026 · strength 0.51
  4. Ksenija Korać · 3 shared papers, 2021–2023 · strength 0.48
  5. Tyler Sniegowski · 3 shared papers, 2021–2023 · strength 0.48
  6. Mosharaf Mahmud Syed · 2 shared papers, 2023–2026 · strength 0.45
  7. Bradley K. Schniers · 3 shared papers, 2020–2022 · strength 0.41
  8. Aimin Cai · 1 shared paper, 2020 · strength 0.11
  9. Hailun Zheng · 1 shared paper, 2020 · strength 0.11
  10. Carolina Torres · 1 shared paper, 2020 · strength 0.09
  11. Paul J. Grippo · 1 shared paper, 2020 · strength 0.09
  12. Veena Coothankandaswamy · 1 shared paper, 2016 · strength 0.06
  13. Pankaj Kumar Singh · 1 shared paper, 2016 · strength 0.06
  14. Dung‐Tsa Chen · 1 shared paper, 2012 · strength 0.03
  15. Domenico Coppola · 1 shared paper, 2012 · strength 0.03
  16. Barbara Ann Centeno · 1 shared paper, 2012 · strength 0.03
  17. James F. Helm · 1 shared paper, 2012 · strength 0.03
  18. Mokenge Peter Malafa · 1 shared paper, 2012 · strength 0.03
  19. Jong Y. Park · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.